Molecular profiling in Parkinsonian syndromes: CSF biomarkers.

Clinica Chimica Acta; International Journal of Clinical Chemistry
Federico Paolini PaolettiLucilla Parnetti

Abstract

An accurate and early diagnosis of degenerative parkinsonian syndromes is a major need for their correct and timely therapeutic management. The current diagnostic criteria are mostly based on clinical features and molecular imaging. However, diagnostic doubts often persist especially in the early stages of diseases when signs are slight, ambiguous and overlapping among different syndromes. Molecular imaging may not be altered in the early stages of diseases, also failing to discriminate among different syndromes. Cerebrospinal fluid (CSF) represents an ideal source of biomarkers reflecting different pathways of neuropathological changes taking place in the brain and preceding the clinical onset. The aim of this review is to provide un update on CSF biomarkers in parkinsonian disorders, discussing in detail their association with neuropathological correlates. Their potential contribution in differential diagnosis and prognostic assessment of different parkinsonian syndromes is also discussed. Before entering the clinical use both for diagnostic and prognostic purposes, these CSF biomarkers need to be thoroughly assessed in terms of pre-analytical and analytical variability, as well as to clinical validation in independent cohorts.

Citations

Feb 25, 2021·Tissue Engineering and Regenerative Medicine·Silvia BarbonMaria Teresa Conconi

❮ Previous
Next ❯

Related Concepts

Related Feeds

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.

Related Papers

Seminars in Neurology
G W Paulson, A Aotsuka
Bulletins et mémoires de la Société médicale des hôpitaux de Paris
G GUIOT, S BRION
© 2021 Meta ULC. All rights reserved